In the context of KRAS, it was shown that in the early phase of NSCLC, TILs express PD-1, and that PD-1 blockade in a KRAS-mutant murine NSCLC model increased both T cell proliferation and helper T cell activity. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.